NK cell ther­a­py-fo­cused biotech eyes SPAC deal

A small, San­ta Ana-based biotech cre­at­ed in 2017 is look­ing to en­ter a SPAC deal as it lays out plans to be­gin tri­als in its lead cell ther­a­py can­di­dates and bring on new ex­ec­u­tives.

Graf Ac­qui­si­tion Corp. IV and NKGen Biotech an­nounced Thurs­day, with few oth­er de­tails, that the two com­pa­nies signed a non-bind­ing let­ter of in­tent to “pur­sue a busi­ness com­bi­na­tion.” Graf Ac­qui­si­tion II and III with­drew their IPOs last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER